CDC-RFA-GH22-2234: Delivering Comprehensive and Sustainable HIV/AIDS Clinical and Community Services to Achieve HIV Epidemic Control in Subnational Units in Nigeria under the President's Emergency Plan for AIDS Relief (PEPFAR)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - CGH notices from 2021.
Centers for Disease Control - CGH offered grants to any type of organization. It expected to make about 4 awards. Applications closed on February 28, 2022.
From the official notice on Grants.gov, last changed February 4, 2022. Checked November 7, 2026.
- Expected awards4
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | December 28, 2021 |
|---|---|
| Deadline | February 28, 2022 |
| Archived by Grants.gov | May 3, 2022 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the program's money (62% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $160,000,000 for Year 1, subject to the availability of funds. However, for this NOFO, applicants should apply to the Average One Year Award Amount/Approximate Average Award amount of $40,000,000 instead of applying to the full $160,000,000 Approximate Total Fiscal Year Funding amount for Year 1. Applicants should develop a proposal to spend $40,000,000 carrying out activities in 4-5 states (including at least 1 high burden state) in Nigeria. Exact funding amounts and the geographic scope for each award under this NOFO will be determined at the time of award. This NOFO aims to support the Government of Nigeria (GON) to achieve HIV epidemic control across all CDC-supported states within age and sex bands. CDC implementing partners (IPs) will provide high-quality comprehensive HIV care and treatment clinical and community services to reach the UNAIDS 95-95-95 targets by 2030. This NOFO aims to integrate HIV service delivery with the management of other non-communicable and infectious diseases such as TB and COVID-19 by delivering client-centered interventions prioritizing at risk and marginalized populations. While the country program has made considerable progress, to reach the goal of HIV epidemic control, continued scale-up of antiretroviral therapy (ART) is needed. The accelerated scale-up of ART in combination with high impact prevention, treatment, and retention strategies can quicken the pace of the HIV response to reduce HIV incidence and HIV-related mortality. This NOFO will support the use of evidence-based, client-centered models of differentiated care with real-time data collection, analysis, and quality improvement to increase program performance and accountability, thereby placing the country on the path of ending the HIV epidemic. The recipient(s) will also jointly develop a phased sustainability framework with the GON to guide program implementation across all sub-national units (SNUs) to strengthen local partnerships and commitment to achieving sustainable HIV epidemic control.
Who has won Global AIDS grants before
From fiscal 2021 to 2025, Global AIDS (93.067) awarded $7.6 billion across 521 grant awards, an average of $14.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 32 | $684 million |
| Elizabeth Glaser Pediatric AIDS Foundation | District of Columbia | 13 | $387 million |
| Management and Development for Health | 5 | $282 million | |
| Apin Public Health Initiatives LTD/Gte | 4 | $209 million | |
| University of Washington | Washington | 8 | $195 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-GH22-2234 still open?
No. It closed on February 28, 2022.
Who can apply for Delivering Comprehensive and Sustainable HIV/AIDS Clinical and Community Services to Achieve HIV Epidemic Control in Subnational Units in Nigeria under the President's Emergency Plan for AIDS Relief (PEPFAR)?
Centers for Disease Control - CGH accepted applications from any type of organization.
What is the deadline for Delivering Comprehensive and Sustainable HIV/AIDS Clinical and Community Services to Achieve HIV Epidemic Control in Subnational Units in Nigeria under the President's Emergency Plan for AIDS Relief (PEPFAR)?
Closed February 28, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Global AIDS grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, Elizabeth Glaser Pediatric AIDS Foundation, Management and Development for Health. The program made 521 awards worth $7.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)